Skip to main content
SpringerLink
Log in

Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom

  • Original Research Article
  • Published:
Applied Health Economics and Health Policy Aims and scope Submit manuscript

Abstract

Background

CT-P13 subcutaneous (SC)—the first and only SC version of infliximab—is approved by the European Medicines Agency for the treatment of rheumatoid arthritis (RA). This new mode of infliximab administration will allow patients to self-inject at home, significantly reducing the number of outpatient visits and costs of intravenous (IV) administration. This paper describes the economic impact of introducing CT-P13 SC to the market from the UK societal perspective.

Objective

The budget impact analysis was conducted to assess the financial impact of the adoption of CT-P13 SC over a 5-year period.

Methods

A prevalence-based budget impact model was developed incorporating epidemiological data, administration cost data, and market share data. The analysis compared a “world with” CT-P13 SC scenario to a “world without” CT-P13 SC. A sensitivity analysis included dose escalation up to 4.1 mg/kg to reflect the real-world care delivery setting.

Results

Compared to the “world without” scenario, the introduction of CT-P13 SC resulted in cost savings of ₤69.3 million in the UK over a 5-year period. In the scenario analysis, the saving increased to ₤173.5 million over 5 years.

Conclusion

Use of CT-P13 SC may lead to substantial cost savings for the UK society.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. The Burden of Rheumatoid Arthritis across Europe: a Socioeconomic Survey (BRASS): British Society of Rheumatology.

  2. A D-G. Rheumatoid arthritis. 2019. https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Rheumatoid-Arthritis. Cited 24 August 2020.

  3. (NRAS) NRAS. What is RA? https://www.nras.org.uk/what-is-ra-article#:~:text=About%201%25%20of%20the%20population,a%20bit%20older%20for%20men. Cited 27 July 2020.

  4. Institute for Health Metrics and Evaluation. GBD results tool. Global burden of disease data resources. 2017. http://ghdx.healthdata.org/gbd-results-tool.

  5. Freeman J. RA facts: what are the latest statistics on rheumatoid arthritis? 2018. https://www.rheumatoidarthritis.org/ra/facts-and-statistics/. Cited 25 Aug 2020.

  6. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Prim. 2018;4(1):18001.

    Article  Google Scholar 

  7. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology. 2000;39(2):122–32.

    Article  CAS  Google Scholar 

  8. Sokka T, Krishnan E, Häkkinen A, Hannonen P. Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum. 2003;48(1):59–63.

    Article  Google Scholar 

  9. Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):123–30.

    Article  Google Scholar 

  10. Tuominen R, Tuominen S, Suominen C, Möttönen T, Azbel M, Hemmilä J. Perceived functional disabilities among rheumatoid arthritis patients. Rheumatol Int. 2010;30(5):643–9.

    Article  Google Scholar 

  11. Leino M, Tuominen S, Pirilä L, Tuominen R. Effects of rheumatoid arthritis on household chores and leisure-time activities. Rheumatol Int. 2015;35(11):1881–8.

    Article  Google Scholar 

  12. Wikström I, Book C, Jacobsson LT. Difficulties in performing leisure activities among persons with newly diagnosed rheumatoid arthritis: a prospective, controlled study. Rheumatology (Oxford). 2006;45(9):1162–6.

    Article  Google Scholar 

  13. GBD Results Tool. Institute for Health Metrics and Evaluation.

  14. Chronic rheumatic conditions. https://www.who.int/chp/topics/rheumatic/en/. Cited 25 Aug 2020.

  15. Living longer: how our population is changing and why it matters. 2018. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/ageing/articles/livinglongerhowourpopulationischangingandwhyitmatters/2018-08-13. Cited 25 Aug 2020.

  16. Morgan E. National life tables, UK: 2016 to 2018. 2019. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/bulletins/nationallifetablesunitedkingdom/2016to2018. Cited 25 Aug 2020.

  17. Belloni BFA. Ageing and health expenditure. 2019. https://publichealthmatters.blog.gov.uk/2019/01/29/ageing-and-health-expenditure/. Cited 25 Aug 2020.

  18. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77.

    Article  Google Scholar 

  19. Papadopoulos CG, Gartzonikas IK, Pappa TK, Markatseli TE, Migkos MP, Voulgari PV, et al. Eight-year survival study of first-line tumour necrosis factor α inhibitors in rheumatoid arthritis: real-world data from a university centre registry. Rheumatol Adv Pract. 2019;3(1):rkz007.

  20. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 2006;54(4):1075–86.

    Article  CAS  Google Scholar 

  21. Perdriger A. Infliximab in the treatment of rheumatoid arthritis. Biologics. 2009;3:183–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Agency EM. Remicade. Infliximab in the treatment of rheumatoid arthritis. 2019. Cited 25 Aug 2020.

  23. Holroyd CR, Parker L, Bennett S, Zarroug J, Underhill C, Davidson B, et al. Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis. Clin Exp Rheumatol. 2018;36(1):171–2.

    PubMed  Google Scholar 

  24. Moots RJ, Curiale C, Petersel D, Rolland C, Jones H, Mysler E. Efficacy and safety outcomes for originator TNF inhibitors and biosimilars in rheumatoid arthritis and psoriasis trials: a systematic literature review. BioDrugs. 2018;32(3):193–9.

    Article  CAS  Google Scholar 

  25. Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology. 2012;51(suppl_6):vi28–36.

  26. Schwartzman S, Morgan GJ, Jr. Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res Ther. 2004;6(Suppl 2):S19–23.

  27. Janssen Biologics B.V. Remicade 100 mg powder for concentrate for solution for infusion. [Summary of Product Characteristics]. European medicines agency website. 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/remicade. Accessed 25 Aug 2020.

  28. Celltrion Healthcare Hungary Kft. Remsima 100 mg powder for concentrate for solution for infusion [Summary of Product Characteristics]. European medicines agency website. 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/remsima#product-information-section. Accessed 24 Aug 2020.

  29. Schmier J, Ogden K, Nickman N, Halpern MT, Cifaldi M, Ganguli A, et al. Costs of providing infusion therapy for rheumatoid arthritis in a hospital-based infusion center setting. Clin Ther. 2017;39(8):1600–17.

    Article  Google Scholar 

  30. Tetteh EK, Morris S. Evaluating the administration costs of biologic drugs: development of a cost algorithm. Health Econ Rev. 2014;4(1):26.

    Article  Google Scholar 

  31. Soini EJ, Leussu M, Hallinen T. Administration costs of intravenous biologic drugs for rheumatoid arthritis. Springerplus. 2013;2:531.

    Article  Google Scholar 

  32. Sørensen J, Linde L, Hetland ML. Contact frequency, travel time, and travel costs for patients with rheumatoid arthritis. Int J Rheumatol. 2014;2014:285951.

    Article  Google Scholar 

  33. Fautrel B, Woronoff-Lemsi MC, Ethgen M, Fein E, Monnet P, Sibilia J, et al. Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in France. Jt Bone Spine. 2005;72(6):550–6.

    Article  Google Scholar 

  34. Walsh CA, Minnock P, Slattery C, Kennedy N, Pang F, Veale DJ, et al. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2007;46(7):1148–52.

    Article  CAS  Google Scholar 

  35. Stoner KL, Harder H, Fallowfield LJ, Jenkins VA. Intravenous versus subcutaneous drug administration which do patients prefer? A systematic review. Patient Patient Cent Outcomes Res. 2015;8(2):145–53.

    Article  Google Scholar 

  36. Navarro-Millán I, Herrinton LJ, Chen L, Harrold L, Liu L, Curtis JR. Comparative effectiveness of etanercept and adalimumab in patient reported outcomes and injection-related tolerability. PLoS ONE. 2016;11(3):e0149781.

    Article  Google Scholar 

  37. Huynh TK, Ostergaard A, Egsmose C, Madsen OR. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adher. 2014;8:93–9.

    Google Scholar 

  38. Ariza-Ariza R, Navarro-Sarabia F, Hernández-Cruz B, Rodríguez-Arboleya L, Navarro-Compán V, Toyos J. Dose escalation of the anti-TNF-α agents in patients with rheumatoid arthritis. A systematic review. Rheumatology. 2006;46(3):529–32.

    Article  Google Scholar 

  39. Rahman MU, Strusberg I, Geusens P, Berman A, Yocum D, Baker D, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(9):1233–8.

    Article  CAS  Google Scholar 

  40. Westhovens R, Wiland P, Zawadzki M, Ivanova D, Kasay AB, El-Khouri EC, et al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. Rheumatology (Oxford). 2020;60(5):2277–2287

  41. Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44(4):495–507.

    PubMed  Google Scholar 

  42. Salaffi F, Di Carlo M, Farah S, Carotti M. Adherence to subcutaneous anti-TNFα agents in patients with rheumatoid arthritis is largely influenced by pain and skin sensations at the injection site. Int J Rheum Dis. 2020;23(4):480–7.

    Article  CAS  Google Scholar 

  43. Bhoi P, Bessette L, Bell MJ, Tkaczyk C, Nantel F, Maslova K. Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database. BMJ Open. 2017;7(9):e015872.

    Article  Google Scholar 

  44. Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess. 2016;20(35):1–610.

    Article  Google Scholar 

  45. Clare DF, Alexander FC, Mike S, Dan G, Allan F, Lisa W, et al. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2009;21(1):71–5.

    Article  CAS  Google Scholar 

  46. McConnell J, Parvulescu-Codrea S, Behm B, Hill B, Dunkle E, Finke K, et al. Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness. World J Gastrointest Pharmacol Ther. 2012;3(5):74–82.

    Article  Google Scholar 

  47. (ONS) OfNS. United Kingdom population mid-year estimate. 2019. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates. Accessed 10 Oct 2020.

  48. Heald A, Bramham-Jones S, Davies M. Comparing cost of intravenous infusion and subcutaneous biologics in COVID-19 pandemic care pathways for rheumatoid arthritis and inflammatory bowel diseases—a brief UK stakeholder survey. Int J Clin Pract. 2021;e14341.

  49. Consumer price inflation tables. In: Statistics OfN, editor. Office for National Statistics; 2020.

  50. (ONS) OfNS. Average actual weekly hours of work for full-time workers (seasonally adjusted). 2020. https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/earningsandworkinghours/timeseries/ybuy/lms. Cited 4 Nov 2020.

  51. (ONS) OfNS. AWE: whole economy level (£): seasonally adjusted total pay excluding arrears. 2020. https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/earningsandworkinghours/timeseries/kab9/emp. Cited 4 Nov 2020.

  52. N NRAS. ‘I Want to Work’ Survey. 2014.

  53. Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(7):1208–15.

    Article  CAS  Google Scholar 

  54. Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64(5):704–7.

    Article  CAS  Google Scholar 

  55. Caporalia R, Allanore Y, Altenc R, Combed B, Dureze P, Iannonef F, Nurmohamedg MT, Leei SJ, Kwonj TS, Choij JS, Parki G, Yook DH. Efficacy and safety of infliximab subcutaneous versus adalimumab, etanercept and infliximab intravenous in patients with rheumatoid arthritis: a systematic literature review and treatment comparison. 2020;17(1):85–99.

Download references

Author information

Authors and Affiliations

  1. Celltrion Healthcare, 19, Academy-ro 51, Yeonsu-gu, Incheon, 22014, Republic of Korea

    Han Geul Byun, Minyoung Jang, Hyun Kyeong Yoo & Taek Sang Kwon

  2. Celltrion Healthcare United Kingdom Limited, 1-7 The Switch, The Grove, Slough, UK

    James Potter

Authors
  1. Han Geul Byun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Minyoung Jang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hyun Kyeong Yoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James Potter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Taek Sang Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Taek Sang Kwon.

Ethics declarations

Funding

This research was supported by Celltrion Healthcare.

Conflict of interest

HGB, MYJ, HKY, JP, and TSK report that they have a financial interest in Celltrion Healthcare, a company that may be affected by the research reported in the enclosed paper. All authors are employed by Celltrion Healthcare.

Availability of data and material

All data analysed during this study are included in this published article and its Supplementary Table file.

Code availability

The model is available on request.

Authors’ contributions

Conceptualisation: TSK, MYJ; original draft: HGB, MYJ; editing: HGB, MYJ; data analysis: MYJ, HKY; review: TSK, HKY, JP; supervision: TSK

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 51 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Byun, H.G., Jang, M., Yoo, H.K. et al. Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom. Appl Health Econ Health Policy 19, 735–745 (2021). https://doi.org/10.1007/s40258-021-00673-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40258-021-00673-1

Search

Navigation